XSOLLA
7.8.2024 15:39:31 CEST | Business Wire | Press release
Xsolla, a global video game commerce company, will attend and present at the Devcom Developer Conference and Gamescom 2024, the world's largest computer and video games event, taking place from August 19th to August 23rd in Cologne, Germany, EU. These events will provide the ideal platform for Xsolla to showcase its cutting-edge solutions, designed to create seamless Cross-Play and Cross-Pay experiences for game developers and players. Their powerful new offerings include Xsolla Backend, Xsolla Mobile SDK, and Xsolla Instant Solutions, featuring Instant Web Shop, Instant Game Sales, Instant Launcher, and Instant Cloud Gaming.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240807882430/en/
(Graphic: Xsolla)
Xsolla Backend
Xsolla Backend offers developers a scalable and affordable solution to enhance game functionality and player engagement across all technology platforms. This includes a built-in launcher and website, efficient matchmaking, over 20 game management systems, and robust cross-play and multiplayer functionalities.
Xsolla Mobile SDK
Xsolla's Mobile SDK is designed to enhance revenue streams for mobile game developers by enabling seamless in-game payments and supporting out-of-store builds and in-store processing for in-app purchases (IAP). With compatibility across platforms like AltStore and Epic Games Store Mobile, the SDK also empowers developers to offer a modern payment experience that complies with iOS and Android regulations. It provides global coverage with over 700 payment methods, making it easier than ever for developers to monetize their games and reach a wider audience.
Xsolla Instant Solutions
Xsolla expanded the Instant Web Shop to include offers of Instant Game Sales, Instant Launcher, and Instant Cloud Gaming to enable faster integration and revenue generation for video game developers. Instant Web Shop enables quick setup of online stores with features like personalization and promotions to enhance user engagement and revenue. Instant Game Sales facilitates direct-to-consumer sales by importing content from platforms like Steam and Epic Game Store. Instant Launcher provides a pre-designed app for direct game distribution, supporting various release stages while reducing costs and promoting cross-engagement. Instant Cloud Gaming allows developers to launch a branded cloud gaming platform quickly, offering pre-launch testing and global reach to expand revenue opportunities.
“We’re excited to be back at Gamescom this year and showcase our latest solutions to the global gaming community,” said David Stelzer, President of Xsolla. “Our solutions are crafted to empower developers and publishers with the tools they need to succeed in today’s dynamic landscape. We invite all attendees to visit our booth and see firsthand how Xsolla can elevate their game development and business operations.”
Attendees can visit Xsolla at Hall 2.2, Booth #A-030 B-037, where live demonstrations of Xsolla’s Payments and Web Shop and these latest solution releases will be held throughout the event. Xsolla’s team of experts will be available to answer questions, provide insights, and discuss how these tools can be tailored to meet the unique needs of each developer and publisher.
For more information, connect and book meetings with Xsolla at the Devcom Developer Conference and Gamescom 2024, visit xsolla.events/gamescom24
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Raleigh, Tokyo, and cities around the world, Xsolla supports major gaming titles like Valve, Twitch, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit xsolla.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240807882430/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom